drugset

drugset / Trial / NCT00406458

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

NCT00406458 ↗

Phase 2 Completed 110 enrolled Sangamo Therapeutics Juvenile Diabetes Research Foundation · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to study the clinical effects of the investigational drug, SB-509 versus placebo in patients with diabetic neuropathy.

Timeline

Start: 2006-11
Primary completion: 2008-12
Completion: 2009-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SB-509	Unknown	60 mg	Intramuscular

Indications